A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

NCT05267470 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

74

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision not due to safety concerns

Conditions

Squamous-Cell Non-Small-Cell Lung Cancer

Interventions

DRUG: Bemarituzumab
DRUG: Docetaxel
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Nab-paclitaxel

Sponsor

Amgen